Aptalis Pharma to launch $200 million add-on term loan B on Friday

By Sara Rosenberg

New York, March 29 - Aptalis Pharma Inc. (formerly known as Axcan Holdings Inc.) will hold a conference call on Friday to launch a $200 million five-year senior secured incremental term loan B, according to a market source.

Bank of America Merrill Lynch, Barclays Capital Inc. and RBC Capital Markets LLC are the lead banks on the deal.

Proceeds will be used to prepay $195 million of senior unsecured notes.

Aptalis is a Bridgewater, N.J.-based specialty pharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.